Status:
UNKNOWN
Multiepitope Peptide Vaccination in Melanoma
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients
Eligibility Criteria
Inclusion
- Metastatic melanoma
- HLA-A1, -A2, -A24, -B44
Exclusion
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00153569
Start Date
March 1 2003
End Date
September 1 2005
Last Update
May 26 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hem&Onc Charité CBF
Berlin, Germany, 12200